Display Settings:

Format

Send to:

Choose Destination
    Pharmacogenomics. 2008 Oct;9(10):1531-41.

    Current trends in screening across ethnicities for hypersensitivity to abacavir.

    Source

    Department of Pharmacokinetics and Pharmacogenomics, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain. sonia_r_novoa@hotmail.com

    Abstract

    Abacavir is a potent nucleoside analog reverse transcriptase inhibitor approved for the treatment of HIV infection. Approximately 5-8% of Caucasian patients receiving abacavir develop a hypersensitivity reaction, characterized by rash, fever and, occasionally, multisystemic involvement. Rechallenge with the drug can be fatal. The discovery of the mechanisms involved in this hypersensitivity reaction and the identification of tools for its prediction are the subject of this review. The most relevant finding is the recognition of a strong association between one specific haplotype at the HLA complex type I, HLA-B*5701, and the abacavir hypersensitivity reaction. The heterogeneity in the prevalence of HLA-B*5701 across distinct ethnicities accounts for differences in the risk of abacavir hypersensitivity reactions in distinct populations.

    PMID:
    18855539
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Atypon

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk